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 
Abstract— High-throughput genotyping and increased 
availability of electronic health records (EHR) are giving 
scientists the unprecedented opportunity to exploit routinely 
generated clinical data to advance precision medicine. The 
extent to which national structured EHR in the United Kingdom 
can be utilized in genome-wide association studies (GWAS) has 
not been systematically examined. In this study, we evaluate the 
performance of an EHR-derived acute myocardial infarction 
phenotype (AMI) for performing GWAS in the UK Biobank. 
I. INTRODUCTION 
GWAS traditionally leverage longitudinal studies to 
manually derive disease cases/controls. Consequently, they 
often examine a small set of broad phenotypes. With 
decreasing genotyping costs and increased availability of 
computational resources, there is an unmet need for larger, 
phenotypically-rich datasets to drive precision medicine at 
scale [1].  EHR contain a wealth of information (e.g. 
diagnoses, laboratory measurements, prescriptions) that can 
potentially compose high-resolution phenotypes. While 
significant progress has been made by eMERGE [2] in the US, 
the extent to which national, structured UK EHR can be 
utlized has not been systematically investigated. In this study, 
we perform a GWAS in the UK Biobank using an 
EHR-derived AMI phenotype and evaluate our findings.  
II. METHODS 
The UK Biobank [3] is an extensively-phenotyped and 
genotyped (Affymetrix, 820,967 SNPs) cohort of 502,640 UK 
participants.  We performed sample and SNP quality control 
procedures in participants with genetic data (n=120,286) and 
derived the final cohort (n=112,142). We applied a 
previously-validated AMI EHR phenotype from CALIBER 
[4] which links structured national UK EHR sources from 
primary/secondary care and mortality in ~15 million patients. 
We utilized diagnostic (ICD-10 I21-I23, I24.1, I25.2, ICD-9 
410-414, 4297) and procedure codes (OPCS-4: K50.2-3) to 
define cases - non-cases were coded as “unaffected”. We used 
a logistic regression to test the association between 10 million 
expected allelic dosages and AMI controlling for sex, batch, 
genotyping chip, recruitment centre and PC 1-15. Evaluation 
was through comparison with CARDIoGRAMplusC4D [5]. 
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Figure 1.  Genome-wide Manhattan plot for AMI 
III. RESULTS 
Using an EHR AMI phenotype, we identified 3,408 affected 
and 108,734 unaffected participants. We discovered 69 
non-independent genetic variants spanning (Fig 1.) regions on 
chromosomes 6 and 9 (e.g. 9p21 loci) showing genome-wide 
significance (p<5x10-8, λ=1.02). Consistent direction and 
magnitude of associations were replicated in 67 (97%) of 
previously reported genetic variants [5]. 
IV. DISCUSSION 
Using an EHR-derived AMI phenotype, we identified 
positively-associated variants across previously reported loci 
from conventional GWAS. Transforming raw EHR to 
research-ready phenotypes however is challenging since data 
are collected for various purposes and robust high-throughput 
phenotyping methods are required. EHR phenotypes can 
potentially be used to increase sample and phenotypic 
resolution and drive the discovery of clinically-actionable 
associations. 
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